ArticleInternational wound journal2026
Immunoinflammatory Profile of FGF-18, IL-35 and Glutamic Acid Decarboxylase in Patients With Diabetic Foot Ulcers.
Article in International wound journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diabetic foot ulcer (DFU) is a serious problem that may cause amputation of the lower extremities in patients with diabetes. The present research aimed to assess the localised tissue expression and potential immunoinflammatory crosstalk among fibroblast growth factor-18 (FGF-18), glutamic acid decarboxylase (GAD) and interleukin-35 (IL-35) in DFU compared to non-diabetic controls (NDCs), while also examining the systemic serum levels of FGF-18 and IL-35. Venous blood was collected from 80 patients with DFU and 100 NDC, and the concentrations of serum IL-35, FGF-18 and blood haemoglobin A1c (HbA1c) were analysed. Aseptically collected biopsy samples were obtained from FUs of 30 type 2 diabetes (T2D) patients and from accidental foot wounds of 30 NDC. Biopsies were preserved in formalin (10%) until paraffin blocks were prepared. The immunohistochemical methodology used antibodies specifically to identify tissue FGF-18, GAD and IL-35 in the soft tissue specimens. The tissue expression of FGF-18, IL-35 and GAD was significantly higher in DFU compared to NDC (p ≤ 0.0001), suggesting a strong localised immunoinflammatory role, whereas serum levels of FGF-18 and IL-35 remained statistically unchanged. Furthermore, significant positive correlations observed between tissue IL-35 and FGF-18 (r = 0.67, p ≤ 0.05) and between tissue IL-35 and GAD (r = 0.60, p ≤ 0.05) indicate robust immunoinflammatory crosstalk. The marked and correlated elevation of FGF-18, IL-35 and GAD specifically within DFU tissue, without changes in serum levels of FGF-18 and IL-35, establishes a robust, compartmentalised immunoinflammatory axis that drives chronic pathology and presents novel targets for localised therapeutic intervention.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.